Biota makes major antiviral discovery
Biota Holdings Limited announced today that it has discovered a new class of orally-effective, potent antivirals against RSV (respiratory syncytial virus) infection. Biota has filed worldwide patents and selected a lead candidate with a series of backups for further preclinical development prior to human clinical trials. RSV infection is an important medical need and already a billion-doll...Biota Initiates Drug Testing War against Common Cold
Human clinical trials of BTA798 anti-viral therapy for common cold have been initiated by Biota. The compound has already proven to be effective against the human rhinovirus // in lab experiments conducted on animal models. HRV currently accounts for nearly 50% and 75% of common cold suffered by adults and children respectively. If successful results are obtained, the drug would soon be...